Eucomed asks: is device reuse really worth it?:
This article was originally published in Clinica
Executive Summary
The costs of validating whether a medical device can safely be reprocessed and reused could be anything between $7,000 and $50,000, according to the European medical device industry association, EUCOMED. In a recent position paper, it argues that reprocessing creates many additional, often unforeseen, costs. These are normally related to stocking, storing, distribution and recording. But they may also arise because of patients needing treatment for infections resulting from reused devices, and even in compensation for medical negligence claims.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.